Signal Tracker

A living tracker of high-impact claims in longevity science and healthspan research, with linked evidence from published coverage.

therapeutics Senolytic therapies are showing clinical efficacy in human trials supported 7 posts

Tracks evidence that drugs targeting senescent cells (senolytics like dasatinib+quercetin, fisetin) are demonstrating measurable benefits in human clinical trials.

therapeutics mTOR inhibition is extending healthspan in clinical settings emerging 1 post

Tracks clinical and preclinical evidence that rapamycin and rapalogs improve age-related outcomes and extend healthy lifespan.

biomarkers Epigenetic clocks are becoming standard biological age measures supported 1 post

Tracks adoption of DNA methylation-based aging clocks (Horvath, GrimAge, DunedinPACE) as validated biomarkers in research and clinical practice.

biomarkers Multi-omic blood panels are enabling personalized aging assessments emerging 0 posts

Tracks whether composite blood biomarker panels (proteomics, metabolomics) are being validated for predicting biological age and disease risk.

No linked evidence yet.

nutrition Caloric restriction mimetics are advancing toward clinical use emerging 0 posts

Tracks compounds that mimic fasting or caloric restriction benefits (metformin, spermidine, NAD+ precursors) moving through trials and adoption.

No linked evidence yet.

nutrition Microbiome composition is linked to aging trajectories supported 8 posts

Tracks research connecting gut microbiome diversity and specific microbial signatures to healthspan, inflammaging, and age-related disease.

technology AI is accelerating drug discovery for age-related diseases emerging 0 posts

Tracks how machine learning and AI platforms are identifying novel longevity drug candidates, repurposing existing drugs, and shortening development timelines.

No linked evidence yet.

technology Gene therapies targeting aging pathways are entering clinical development emerging 0 posts

Tracks gene therapy approaches (telomerase activation, Yamanaka factors, CRISPR-based interventions) aimed at reversing or slowing biological aging.

No linked evidence yet.

policy Regulatory bodies are beginning to recognize aging as a treatable condition emerging 0 posts

Tracks regulatory developments (FDA, EMA) around classifying aging as an indication and creating pathways for longevity therapeutics approval.

No linked evidence yet.

policy Venture capital and public funding for longevity research is accelerating emerging 0 posts

Tracks investment trends in longevity biotech, including VC rounds, government grants, and corporate R&D commitments to aging research.

No linked evidence yet.